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Abstract
Epigenetics is defined as the heritable chances that affect gene expression 
without changing the DNA sequence. Epigenetic regulation of gene 
expression can be through different mechanisms such as DNA methylation, 
histone modifications and nucleosome positioning. MicroRNAs are short 
RNA molecules which do not code for a protein but have a role in post-
transcriptional silencing of multiple target genes by binding to their 3´ 
UTRs (untranslated regions). Both epigenetic mechanisms, such as DNA 
methylation and histone modifi cations, and the microRNAs are crucial for 
normal differentiation, development and maintenance of tissue-specifi c gene 
expression. These mechanisms also explain how cells with the same DNA 
content can differentiate into cells with different functions. Changes in 
epigenetic processes can lead to changes in gene function, cancer formation 
and progression, as well as other diseases. In the present chapter we will 
mainly focus on microRNAs and methylation and their implications in human 
disease, mainly in cancer.
1To whom correspondence should be addressed (email asli@sund.ku.dk).
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Introduction to microRNAs
miRNAs (microRNAs) are a class of short (approx. 22 nt) endogenous non-
coding RNAs that act as post-transcriptional regulators of gene expression. 
According to the September 2009 release of the microRNA database mirbase 
(http://www.mirbase.org/) there are 10883 miRNA entries from vertebrates, 
insects, plants and viruses discovered either by cloning or bioinformatics 
[1]. Among them 721 are detected in humans. The first member of the 
miRNA family, lin-4, was originally identifi ed in Caenorhabditis elegans as 
a developmental timing regulator [2]. miRNAs play fundamental roles in 
the control of many biological processes such as growth, development, 
differentiation, proliferation and cell death [2,3]. They perform these functions 
by repression of their target genes. Each miRNA may target several hundred 
mRNAs and more than 60% of the mRNAs are predicted to have a miRNA-
binding site in their 3´ UTR (3´ untranslated region). The huge number of 
miRNAs identifi ed and evidence accumulated over the years indicate that 
a vast number of normal and pathological mechanisms are controlled by 
miRNA-mediated regulatory networks (reviewed in [4,5]).
Genomic organization, biogenesis and function
miRNAs can be intergenic, intronic or exonic. Intergenic miRNAs have 
either their own promoters (monocistronic) or share the same promoter 
(polycistronic), whereas the intronic miRNAs are present either singly or in 
clusters using the promoter of their host gene. miRNAs are transcribed in the 
nucleus by RNA polymerase II. They are 5´ capped and 3´ polyadenylated. 
The maturation of miRNAs requires two endonucleolytic cleavage steps 
by RNase III-like enzymes: Drosha and Dicer. Following transcription, 
Drosha processes the primary miRNA transcript (pri-miRNA), which 
can be several kilobases long, into a 60–100 nt hairpin structure named the 
precursor-miRNA (pre-miRNA). Pre-miRNAs are folded into mini-helical 
structures to be recognized by exportin-5, the nuclear export factor carrying 
the pre-miRNAs from the nucleus to the cytoplasm. In the cytoplasm, the 
pre-miRNA hairpin is cleaved at the loop end by Dicer, thereby creating 
a 22 nt RNA duplex comprising the mature miRNA guide strand and the 
miRNA* passenger strand. The mature miRNA is loaded into the RISC 
(RNA-induced silencing complex), whereas the passenger strand is degraded 
(Figure 1). The exact details of the miRNA biogenesis mechanism are still to 
be investigated, and much less is known about the mechanisms regulating the 
expression of miRNAs. Recent studies point out that not all miRNAs are 
created by the same mechanisms. After being loaded into the RISC complex 
mature miRNAs are directed to their binding sites in their target mRNAs. 
In broad terms, this binding leads to repression of mRNA translation by 
one of the following mechanisms: translational block by folding the mRNA 
in an inactive steric conformation, deadenylation and destabilization of the 
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mRNA, cleavage of the mRNA or sequestration in P-bodies (processing 
bodies) (reviewed in [4,6,7]).
miRNAs regulate important biological processes
For many biological functions it is very important to have the miRNA 
expression in balance. Developmental timing, differentiation, organogenesis, 
cell proliferation, apoptosis, differentiation of embryonic stem cells, limb 
development, synaptic development and plasticity, skin differentiation, 
cardiogenesis, normal immune function and regulation of insulin secretion in 
the pancreas are some of the biological functions where miRNAs play a crucial 
role (reviewed in [7]).
miRNA and disease
In the last decade it has become clear that aberrant miRNA deregulation and 
expression is observed in most human malignancies, although it is often not 
clear whether this deregulation is the cause or the effect of the disease. Some of 
the most investigated malignancies are cancers, dysfunctional heart conditions, 
metabolic diseases and viral infections. Very recently a knowledge-base on 
Figure 1. Schematic representation of the process from transcription of a miRNA 
gene in the nucleus to mature regulatory miRNA binding to target mRNA in the 
cytosol
Upon binding to the target mRNA the process may be negatively regulated by different 
mechanisms, i.e. translational repression, mRNA destabilization, mRNA cleavage or sequestration 
in P-bodies.
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the aberrant expression of miRNAs in various diseases was introduced [8]. In 
cancers, miRNAs can act either as oncogenes or tumour suppressors, and a 
multitude of papers have investigated the differential expression of miRNAs in 
tumour tissues and their function in cancer cells and metastatic potential (see 
Table 1 for an overview). Many miRNAs act as tumour suppressor genes and 
they are frequently silenced in cancers. However, the underlying mechanism 
for this is less clear. One explanation is epigenetic silencing of miRNA genes 
and this has now been described in various cancers for several miRNAs. 
Table 1. Overview of various miRNAs that are either down-regulated or 
up-regulated in human tumour tissue
AML, acute myeloid leukaemia; CLL, chronic lymphocytic leukaemia.
miRNA Tumour tissue
Changed expression in 
tumours
Let-7 family Lung, breast, prostate, colon, gastric, 
ovary, CLL
Down-regulated
miR-101 Prostate, liver and bladder Down-regulated
miR-122a Liver Down-regulated
miR-143 Colon, breast, lung, cervix, B-cell Down-regulated
miR-145
miR-15a CLL, prostate, pancreas and multiple 
myeloma
Down-regulated
miR-16-1
miR-155 CLL, Burkitt’s lymphoma, lung, breast, 
pancreas and colon
Up-regulated
miR-221 Leukaemia Down-regulated
miR-222
miR-29 family CLL, AML, breast, colon and lung Down-regulated
miR-34 family Pancreas, colon, breast and liver Down-regulated
miR-372 Testis Up-regulated
miR-373
miR-17-92 cluster Lymphomas, breast, lung, colon, 
stomach and pancreas
Up-regulated
miR-106b-93-25 
cluster
Gastric, colon, prostate and 
neuroblastoma
Up-regulated
miR-21 Glioblastoma, ALM, CLL, Burkitt’s 
lymphoma, breast, colon, pancreas, lung, 
prostate, liver and stomach, cervix, 
head and neck cancers
Up-regulated
miR-221 CLL, thyroid, liver and glioblastoma Up-regulated
miR-222
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Mechanisms such as change in turnover rate or DNA copy number could be 
other reasons for differential expression of miRNAs which need to be further 
investigated [9,10].
Introduction to miRNA and epigenetics
Epigenetic phenomenons such as DNA methylation of CpG islands in 
promoter regions of genes and histone modifications are well known to 
regulate gene expression. The major epigenetic changes in cancer are aberrant 
DNA hypermethylation of tumour suppressor genes, global genomic DNA 
hypomethylation and disruption of the histone modifi cation patterns.
Like classical protein coding genes, miRNA genes are also subject to epi-
genetic regulation and miRNAs can also regulate various components of the 
epigenetic machinery. For a detailed review, see [11].
Epigenetic regulation of miRNA expression in cancer
Several miRNAs are down-regulated in cancer and act as bona fi de tumour 
suppressor genes, and therefore these miRNAs are obvious candidates for 
epigenetic silencing. High-quality papers have been published on the impact 
of epigenetic regulation of miRNA genes with regard to cell proliferation, 
apoptosis, tumour suppressor or oncogenic effects both in cell culture systems, 
in vivo models and in various human primary tumours. The epigenetic status 
has also been correlated with metastatic status and with survival of cancer 
patients, which will be the focus of this part of the chapter. An up-to-date 
overview is presented in Table 2.
The concept of controlling miRNA expression by epigenetic mechanisms 
may be as widespread as for protein coding genes, since half of the miRNA 
genes are associated with CpG islands and miRNA gene methylation is detect-
ed with high frequency in normal and malignant cells [12].
A common approach to identifying epigenetically regulated miRNAs 
has been to treat cancer cells with inhibitors of DNA methylation (e.g. 
5-azacytidine) and/or histone deacetylases [e.g. PBA (4-phenylbutyric acid) or 
TSA (trichostatin A)] and compare miRNA expression to that in untreated cells.
This approach was applied in the fi rst two high-impact publications in this 
fi eld from 2006, which identifi ed a number of epigenetically regulated miR-
NAs in breast and bladder cancer cells [13,14].
It has turned out that epigenetic regulation of miRNA expression is a 
common hallmark in human cancers and that epigenetic tags are associated 
with metastatic status and clinically relevant endpoints, such as disease-free 
survival and overall survival, thereby suggesting their use as biomarkers in can-
cer detection, prognosis, monitoring and predicting response to treatment.
In CRC (colorectal cancer), epigenetically regulated miRNAs have 
been indentifi ed in both cell lines and in tumour tissues. The expression of 
miR-342 was found to be regulated by CpG island methylation. Interestingly, 
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methylation of miR-342 may be specifi c to CRC, since in vitro studies employ-
ing 40 non-CRC cell lines only found partial methylation in a single cell line. 
Analysis of tissue indicated that methylation of miR-342 may be an early event 
in CRC since methylation was detected in 86% of CRC adenocarcinomas and 
in 67% of adenomas [15]. Comparison of normal and colon cancer tissues has 
shown that miR-124a is hypermethylated in 75% of the tumours (n=56) [14]. 
Methylation of miR-124a was also found in tumours from the lungs (48%, 
n=27) and breast (32%, n=22), but not in neuroblastomas or sarcomas [16]. 
Analysis of primary CRC tumours (n=111) and adjacent normal colon (n=17) 
found that miR-34b/c was methylated in 90% of the primary CRC tissues and 
very limited methylation was found in the normal mucosa [17].
In primary breast cancer specimens, aberrant hypermethylation has been 
shown for miR-9-1, miR-124a3, miR-148, miR-152 and miR-663 in 34–86% 
of cases in a series of 71 primary human breast cancer specimens [18]. The 
miR-9-1 gene is hypermethylated in pre-invasive intraductal lesions, suggest-
ing that hypermethylation of miR-9-1 is an early and frequent event in breast 
cancer development.
Two reports have associated methylation of miRNA genes with metastatic 
status of cancer patients.
Bandres et al. [19] identifi ed fi ve down-regulated miRNAs in primary 
CRC, which were located in the vicinity (<1000 bp) of a CpG island. 
Methylation status for three of these were analysed in primary CRC samples 
and adjacent normal tissue, and miR-9-1, miR-129-2 and miR-137 were meth-
ylated in 56% (n=36), 91% (n=34) and 100% (n=31) of primary CRC cases 
respectively. Methylation of miR-9-1 was totally absent in histological normal 
mucosa and methylation was more frequent in stage III and IV compared 
with stage I and II. Importantly, methylation status of miR-9-1 was associated 
with regional nodal invasion, vascular invasion and metastasis in a group of 
32 patients (16 non-methylated and 20 methylated).
In a recent report, direct relation of miRNA hypermethylation and 
metastasis was explored [20]. Cell lines established from lymph node 
metastasis were treated with 5-azacytidine and the miRNA expression 
relative to untreated cells was investigated. These experiments identifi ed 
16 hypermethylated and up-regulated miRNAs, located in the proximity 
of a CpG island. Comparison with methylation status of non-cancerous 
tissues further reduced the number of miRNAs displaying cancer-specifi c 
CpG island hypermethylation. The selected miRs – miR-148a, miR-34b/
c, and miR-9-1/2/3 – were tested in vitro and in vivo for their potential 
involvement in metastasis. Re-introduction of miR-34b/c and miR-148 into 
a metastatic carcinoma cell line, which is hypermethylated and silenced 
for miR-34b/c and miR-148 expression, reduced the migratory capabil-
ity of the cancer cells. Likewise, experiments with nude mice showed 
that re-introduction of miR-34b/c and miR-148 caused reduced tumour 
growth and diminished metastatic potential of the metastatic carcinoma 
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cell line. A collection of primary tumour samples (n=278) from various 
tumour types were analysed and hypermethylation was undetectable in the 
corresponding normal tissue. Notably, hypermethylation of miR-34b/c, 
miR-148 and miR-9-3 in primary tumours was signifi cantly associated with 
those tumours that were positive for metastatic cancer cells in the corre-
sponding lymph nodes (n=207).
In a report focusing on ovarian cancer, eight miRNAs (miR-337, miR-368, 
miR-376a/b, miR-377, miR-410, miR-432, miR-495) located in the chromo-
some 14 miRNA cluster (Dlk1-Gtl2 domain) were identifi ed as potential 
tumour suppressor genes regulated by DNA methylation [21]. An expression 
signature separated late-stage ovarian cancers (n=73) into two distinct clusters. 
Patients belonging to the cluster with low expression of the eight miRNAs 
displayed higher tumour proliferation and had shorter 5-year survival. 
Analysis of other cancer types indicated that down-regulation of the chromo-
some 14 miRNA cluster may be an event common to many human epithelial 
tumours.
The let-7a-3 gene is located in a CpG island and its methylation status was 
analysed in 214 malignant tumours: no correlation between disease stage and 
tumour grade was detected [22]. Although the disease-free survival was not 
associated with methylation of let-7a-3, the patients with low let-7a-3 meth-
ylation (n=138) had signifi cantly worse overall survival than those with high 
methylation (n=67).
Two reports from the same laboratory have analysed epigenetic regulation 
of miRNA expression in ALL (acute lymphoblastic leukaemia) and associated 
it with clinical outcome.
In ALL-derived cell lines, analysis of histone modifi cations around CpG 
islands located in the 5´ UTR of miRNA genes identifi ed 13 miRNA candidate 
genes for epigenetic silencing: miR-9-1/2/3, miR-10b, miR-34b/c, miR-124a1/
a2/a3, miR-132, miR-196b, miR-203 and miR-212 [23]. Methylation of at least 
one in 13 miRNA was found in 65% (n=353) of the ALL human tumours and 
was a strong and independent negative prognostic marker for disease-free sur-
vival and overall survival.
In ALL patients, miR-124 is regulated by CpG island hypermeth-
ylation and histone modifi cations, and re-introduction of miR-124a severely 
reduced tumorigenicity of ALL cells in a xenograft mouse model [24]. The 
miR-124a methylation status was analysed in 353 ALL patients and hyper-
methylation was found in 59%; this correlated with decreased expression 
of miR-124a. Furthermore, hypermethylation signifi cantly correlated with 
higher relapse and mortality rates, and multivariate analysis showed that 
miR-124a is an independent prognostic factor for both disease-free survival 
and overall survival.
Taken together, these results show that DNA demethylation and HDAC 
(histone deacetylase) inhibition can activate expression of miRNAs and further 
large-scale clinical investigations are clearly warranted.
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miRNAs as regulators of epigenetic processes
As well as being regulated by epigenetic mechanisms, miRNAs also play a 
role in controlling the chromatin structure by post-transcriptional regulation 
of chromatin-modifying enzymes (reviewed in [11,25]). Among the predicted 
human miRNA target genes there are a number of genes involved in epigenetic 
regulation, such as the methyl CpG-binding proteins, HMTs (histone 
methyltransferases), chromodomain-containing proteins and HDACs [26]. 
This subset of miRNAs, which directly or indirectly regulate the expression 
levels of effectors of the epigenetic processes, have been termed ‘epi-miRNAs’ 
[11]. Aberrant regulation of miRNA expression plays an important and direct 
role in the aberrant epigenetic silencing of tumour suppressor genes by DNA 
methylation in human cancers (see Table 3).
DNA methylation patterns are laid down during development by 
DNMT3a and DNMT3b (where DNMT is DNA methyltransferase), whereas 
maintenance during replication is facilitated by DNMT1. The fi rst direct link 
between a miRNA and the DNMTs was established between the miR-29 
family (miR-29a/b/c) and DNMT3a and DNMT3b, and other miRNAs 
such as miR-148 and miR-143 have also been indicated as regulators of the 
methylation enzymes. In non-small cell carcinoma of the lung, miR-29 is 
down-regulated, whereas the DNMT3A and DNMT3B expression is increased. 
Re-expression of miR-29 is shown to disrupt the de novo DNA methylation 
and caused general hypomethylation, leading to expression of tumour suppres-
sor genes that are silenced by methylation, which resulted in apoptosis in can-
cer cells both in vitro and in vivo. This study indicated that miR-29 regulates 
the DNMT3 genes in lung cancer and revealed a new mechanism whereby the 
miRNAs indirectly regulate the gene expression through direct regulation of 
epigenetic mechanisms [27]. Another group has shown that overexpression of 
miR-29b in AML (acute myeloid leukaemia) cells resulted in marked reduction 
of DNMT1, DNMT3A and DNMT3B at both the RNA and protein levels. 
They concluded that the expression of miR-29b promoted DNA hypometh-
ylation not only through direct targeting of DNMT3a and DNMT3b, but also 
by decreasing the DNMT1 expression indirectly via down-regulation of Sp1, a 
known transactivating factor of the DNMT1 gene [28].
Furthermore, miR-143 regulates DNMT3a in CRC cells, whereas 
miR-148a and miR-148b represses Dnmt3b expression in mouse cells through 
binding to a highly conserved sequence in its coding region rather than the 3´ 
UTR [29,30]. Benetti et al. [31] proposed a new regulatory pathway for DNA 
methylation involving the mammalian miR-290 cluster (miR-290, miR-291-3p, 
miR-291-5p, miR-292-3p, miR-292-5p, miR-293, miR-294 and miR-295) as an 
important regulator of Rbl2, which in turn acts as a transcriptional repressor 
of Dnmt3a and Dnmt3b causing hypomethylation in the genome, especially in 
the telomeres. The whole cluster is shown to be down-regulated in Dicer-null 
cells in mouse, whereas Rbl2 is increased in expression leading to repression of 
Dnmt3a and Dnmt3b causing DNA methylation defects [31]. However, the 
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regulatory effect of the miR-290 cluster on methylation cannot be shown in 
DICER-knockdown human embryonic kidney cells. This indicates that the 
miR-290 clusters’ effect on DNMTs could be cell-type- or species-specifi c 
[32]. Recently, a completely new mechanism was suggested for regulation of 
gene expression by miRNAs in moss. Khraiwesh et al. propose that initiation 
of epigenetic silencing by DNA methylation is regulated according to the ratio 
of the miRNA and its target mRNA [33].
miRNAs also regulate the expression of HDACs and HMTs. HDAC4 
is shown to be a direct target of miR-1 and miR-140 [34,35]. A new miRNA 
HDAC4 regulatory mechanism has been revealed in ALS (amyotrophic lateral 
sclerosis) which is the most common adult motor neuron disease. miR-206 is 
shown to delay the progression of ALS, and HDAC4 is both computation-
ally and experimentally shown to be a target of miR-206. Interestingly, in 
miR-206−/− animals the HDAC4 protein expression is increased in skel-
etal muscles, whereas Hdac4 mRNA levels were not changed. This indicated 
that miR-206 acts upon Hdac4 by translational inhibition rather than at the 
transcription level [36]. miR-1 and miR-499 are indicated in differentiation of 
cardiomyocytes, possibly by repression of HDAC4 and SOX6 genes [37].
miR-449a targets HDAC1, which is up-regulated in many cancer forms. 
miR-449a is down-regulated in cancer, but introduction to prostate cancer 
cells resulted in cell-cycle arrest and apoptosis [38]. Similarly re-expression 
of miR-101 in cancer models also resulted in inhibition of cancer formation. 
miR-101 targets EZH2, the catalytic subunit of the Polycomb repressive 
complex 2 responsible for histone H3 Lys27 trimethylation, a mark of epige-
netic repression, and can alter the chromatin structure globally [39,40]. Li et 
al. [41] identifi ed a new miRNA (miR-2861) in primary mouse osteoblasts that 
promotes osteoblast differentiation by repressing HDAC5 expression at the 
post-transcriptional level.
Conclusions
Recently, the molecular mechanisms of epigenetic regulation of miRNA 
expression and miRNA-mediated control of the epigenetic machinery have 
attracted much attention, especially in cancer research. By now it is apparent 
that some miRNA genes are regulated by DNA CpG island hypermethylation 
and chromatin modifications. Interestingly, these epigenetic marks are 
potential biomarkers since significant correlations with survival of cancer 
patients have been found. Likewise, it is also clear that miRNAs regulate 
various components of the epigenetic machinery and thereby contribute to the 
regulation of the expression of other genes.
It is essential to explore in more detail this new layer of complexity in 
gene regulation to improve our understanding of the regulation of the human 
genome. Importantly, these new insights on the intertwined relationship 
between miRNA and epigenetics are likely to lead to novel revolution-
ary anti-cancer therapeutic approaches. Such approaches may be targeting 
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components of the epigenetic network to cause re-expression of miRNA 
tumour suppressor genes or directly targeting mature miRNAs or re-expressing 
miRNAs in order to directly affect target genes and regulate epigenetic feed-
back loops.
Summary
• miRNAs are small non-protein coding molecules that regulate more 
than 30% of the protein coding genes.
• miRNAs play an important role in many biological processes such as 
differentiation, organ development and proliferation.
• In cancer and some other diseases such as diabetes, neurological and 
cardiac diseases, a perturbed miRNA expression is found in the rel-
evant tissues.
• Some miRNAs are regulated by epigenetic mechanisms, especially by 
methylation.
• Methylation status of some miRNA genes correlates with survival of 
cancer patients.
• miRNAs may regulate the epigenetic machinery directly or indirectly 
by targeting enzymes such as DNMTs or HDACs.
The Wilhelm Johannsen Centre for Functional Genome Research is established by the 
Danish National Research Foundation.
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